Trust Co. of Vermont Purchases 1,023 Shares of Bristol Myers Squibb Company $BMY

Trust Co. of Vermont lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 44,871 shares of the biopharmaceutical company’s stock after buying an additional 1,023 shares during the quarter. Trust Co. of Vermont’s holdings in Bristol Myers Squibb were worth $2,077,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. OLD Point Trust & Financial Services N A lifted its stake in shares of Bristol Myers Squibb by 9.7% in the second quarter. OLD Point Trust & Financial Services N A now owns 16,301 shares of the biopharmaceutical company’s stock worth $755,000 after acquiring an additional 1,440 shares during the period. MBA Advisors LLC lifted its stake in shares of Bristol Myers Squibb by 13.0% in the second quarter. MBA Advisors LLC now owns 6,766 shares of the biopharmaceutical company’s stock worth $313,000 after acquiring an additional 776 shares during the period. Emerald Advisors LLC lifted its stake in shares of Bristol Myers Squibb by 18.4% in the second quarter. Emerald Advisors LLC now owns 19,293 shares of the biopharmaceutical company’s stock worth $893,000 after acquiring an additional 2,995 shares during the period. HCR Wealth Advisors lifted its stake in shares of Bristol Myers Squibb by 4.5% in the second quarter. HCR Wealth Advisors now owns 10,671 shares of the biopharmaceutical company’s stock worth $494,000 after acquiring an additional 458 shares during the period. Finally, Janney Capital Management LLC lifted its stake in shares of Bristol Myers Squibb by 1.7% in the second quarter. Janney Capital Management LLC now owns 40,993 shares of the biopharmaceutical company’s stock worth $1,898,000 after acquiring an additional 695 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wall Street Zen lowered Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target on the stock. in a research note on Tuesday, August 5th. Citigroup dropped their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, August 1st. Finally, Daiwa America lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $56.38.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $47.39 on Thursday. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The stock’s 50 day moving average is $46.49 and its 200-day moving average is $48.85. The firm has a market capitalization of $96.47 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 2.31 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period in the prior year, the firm earned $2.07 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.2%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is presently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.